Showing 5291-5300 of 9117 results for "".
- Galderma Launches New Rosacea Public Awareness Campaignhttps://practicaldermatology.com/news/galderma-launches-new-rosacea-public-awareness-campaign/2460508/Galderma is partnering with rosacea patient and celebrity stylist Brad Goreski for the national awareness campaign, Face Up to Rosacea, to encourage people frustrated with this chronic skin condition to take actio
- Skin Diseases Highly Common in Older Adultshttps://practicaldermatology.com/news/skin-diseases-highly-common-in-older-adults/2460507/Fully 80 percent of adults aged 70 to 93 have at least one skin disease that required treatment, and the most common conditions were fungal skin infections, rosacea, actinic keratosis, and eczema, according to a new study in the 
- AmorePacific Launches New Woke Skincare Brandhttps://practicaldermatology.com/news/amorepacific-launches-new-woke-skincare-brand/2460503/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In addition, Enough
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinoma
- Merz Aesthetics Rolls Out “Confidence to Be” Branding Platform and Other Changeshttps://practicaldermatology.com/news/merz-aesthetics-rolls-outconfidence-to-be-branding-platform-and-other-changes/2460497/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Meet Amber Edwards, Alastin Skincare’s New Chief Commercial Officerhttps://practicaldermatology.com/news/meet-amber-edwards-alastin-skincares-new-chief-commercial-officer/2460485/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International Strategic Ma
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil